Press Releases May 22, 2026 07:30 AM

Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference

Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference

By Maya Rios RGEN

Repligen Corporation, a leader in bioprocessing technologies, announced its participation in the William Blair 46th Annual Growth Stock Conference with a presentation by its CEO on June 3rd. The presentation will provide a company overview and highlight its focus on innovative bioprocessing technologies supporting biological drug manufacturing.

Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
RGEN

Key Points

  • Repligen focuses on bioprocessing technologies critical to the manufacturing of biological drugs, serving biopharmaceutical developers and CDMOs worldwide.
  • The company operates globally with headquarters in Waltham, Massachusetts and manufacturing sites in the U.S. and Europe, underscoring its international footprint in life sciences.
  • Participation in the William Blair Growth Stock Conference provides a platform to attract investor attention and communicate growth strategies.

WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3rd at 10:40 a.m. CT.

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
[email protected]


Risks

  • The company's performance and growth prospects depend heavily on the biopharmaceutical sector, which can be affected by regulatory changes and market dynamics.
  • Global manufacturing operations expose Repligen to geopolitical and supply chain risks impacting production and costs.
  • Market reception to the presentation depends on new strategic updates or financial disclosures; lack of significant news may limit immediate stock impact.

More from Press Releases

Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026